

# Biological properties and clinical applications of berberine

Danyang Song<sup>1</sup>, Jianyu Hao (✉)<sup>1</sup>, Daiming Fan (✉)<sup>1,2</sup>

<sup>1</sup>Department of Gastroenterology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China; <sup>2</sup>State key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an 710032, China

© Higher Education Press 2020

**Abstract** Berberine, an isoquinoline alkaloid isolated from the Chinese herb *Coptis chinensis* and other *Berberis* plants, has a wide range of pharmacological properties. Berberine can be used to treat many diseases, such as cancer and digestive, metabolic, cardiovascular, and neurological diseases. Berberine has protective capacities in digestive diseases. It can inhibit toxins and bacteria, including *Helicobacter pylori*, protect the intestinal epithelial barrier from injury, and ameliorate liver injury. Berberine also inhibits the proliferation of various types of cancer cells and impedes invasion and metastasis. Recent evidence has confirmed that berberine improves the efficacy and safety of chemoradiotherapies. In addition, berberine regulates glycometabolism and lipid metabolism, improves energy expenditure, reduces body weight, and alleviates nonalcoholic fatty liver disease. Berberine also improves cardiovascular hemodynamics, suppresses ischemic arrhythmias, attenuates the development of atherosclerosis, and reduces hypertension. Berberine shows potent neuroprotective effects, including antioxidative, antiapoptotic, and anti-ischemic. Furthermore, berberine exerts protective effects against other diseases. The mechanisms of its functions have been extensively explored, but much remains to be clarified. This article summarizes the main pharmacological actions of berberine and its mechanisms in cancer and digestive, metabolic, cardiovascular, and neurological diseases.

**Keywords** berberine; *Coptis chinensis*; pharmacological properties; mechanism; clinical applications

## Introduction

Berberine (BBR), an isoquinoline alkaloid isolated from the Chinese herb *Coptis chinensis* and other *Berberis* plants, has a wide range of pharmacological properties; its chemical structure is represented in Fig. 1. About 2200 years ago, *C. chinensis* was widely used to treat various diseases and became an important component of Chinese medicinal compounds. *Shennong's Herbal Classic* states “*Coptis chinensis*, is mainly used to prevent or attenuate digestive system disease symptoms, such as abdominal distention and fullness, vomiting and acid regurgitation, diarrhea, jaundice, etc. Besides, it also has potential for the treatment of fever and dizziness, restless, palpitations, hematemesis and epistaxis, conjunctival congestion, toothache, and carbuncle.” However, the mechanisms underlying the pharmacological effects of *C. chinensis* remain

unclear. With the continuous development of modern medical technology, BBR has been discovered to be a major component of *Coptis chinensis* with multiple biological functions (Fig. 2), such as anti-inflammatory [1], anti-infective, antitumor [2], and antiarrhythmic functions and regulation of blood lipids and blood glucose [3], acting on multiple organs and systems of the body.

## Berberine and digestive diseases


### Attenuating intestinal injury

#### *Inhibiting bacteria and toxins*


In 1967, Subbaiah and Amin reported that berberine sulfate has an inhibitory effect on the growth of *Entamoeba histolytica* [4]. Amin also reported the antimicrobial activity of BBR [5]. BBR shows good efficacy in controlling cholera in infant rabbit models. It arrests diarrhea symptoms, prolongs survival time, and prevents death possibly by hindering the formation of toxin by

Received April 22, 2019; accepted October 12, 2019

Correspondence: Daiming Fan, daimingfan@fmmu.edu.cn;  
Jianyu Hao, haojianyu@medmail.com.cn



**Fig. 1** Chemical structure of berberine.



**Fig. 2** Major diseases affected by berberine.

*Vibrio cholerae* [6]. High concentrations of BBR can suppress the growth of *Clostridium difficile* and *Bacillus cereus* by inhibiting spore outgrowth [7]. BBR enhances the antimicrobial effects of azithromycin (AZM) against *Pseudomonas aeruginosa*. The synergism of BBR and AZM not only remarkably decreases the production of virulence factors but also suppresses the inflammatory response by reducing IL-6 and IL-8 and inducing IL-10 [8]. The inflammatory response elicited by *V. cholerae* and *Escherichia coli* can be inhibited by administering BBR in a rabbit ligated intestinal loop model. Furthermore, BBR suppresses the inflammatory response to heat-labile enterotoxin and heat-stable enterotoxin [9]. Berberine is an antimicrobial drug efficient for treating *Eberthella typhosa* infection because it blocks DNA replication with low cell toxicity [10]. In addition, BBR derivatives exert bactericidal activities against methicillin-resistant *Staphylococcus aureus* and enteroinvasive *E. coli*. BBR facilitates the nuclear translocation of transcription factor EB (TFEB) and enhances TFEB-dependent bactericidal activity [11].

#### *Inhibiting secretion and peristalsis*

Berberine shows antidiarrheal pharmacological properties


in infant rabbit models of cholera at least in part due to the BBR suppression of intestinal peristalsis [6]. The antidiarrheal activity of BBR is involved in the inhibition of myoelectric activity and delay of the small intestine transit partly by regulating opioid and  $\alpha$ -adrenergic receptors [12]. In addition, BBR inhibits electrogenic ion transport in rat colonic epithelia, significantly attenuating the short circuit current responses to mast cells induced by anti-rat IgE and other agonists that stimulate chloride secretion [13]. Rabbani has demonstrated the antisecretory activity of BBR in acute diarrhea caused by enterotoxigenic *E. coli* and *V. cholerae* in a randomized controlled trial. This trial also showed that BBR is an effective and safe antisecretory drug without noted adverse effects [14].

#### *Protecting the intestinal epithelial barrier*

BBR can reduce the expression of adenosine deaminase (ADA) mRNA; as a result, the activity of ADA decreases, the adenosine signaling pathway is suppressed, and the small intestinal injury caused by indomethacin is improved by BBR treatment [15]. BBR protects the intestinal epithelial barrier from the inflammatory response by activating the AKT1/SOCS1 pathway [16]; decreasing the levels of proinflammatory cytokines TNF- $\alpha$ , INF- $\gamma$  [17], and IL-10 [18]; reducing macrophage infiltration; and suppressing apoptosis in colonic macrophages and epithelial cells [19]. BBR also inhibits the proliferation of Th1 and Th17 cells and suppresses the phosphorylation of NF- $\kappa$ B to ameliorate intestinal injury and colitis [20]. It is a candidate therapeutic drug for inflammatory bowel disease [21]. BBR maintains the function of the gut-vascular barrier (GVB) by inhibiting the production of nitric oxide and inflammatory cytokines that damage the GVB and increasing the expression of tight junctions and adherent junctions; the increase in transendothelial electrical resistance enhances paracellular permeability [22,23]. BBR is associated with the activation of the Wnt/ $\beta$ -catenin signaling pathway [22]. BBR also augments the secretion of GLP2 to improve barrier function and intestinal permeability [24]. BBR partially reverses the distribution of tight junction proteins in membrane microdomains and attenuates intestinal epithelial tight junction damage by inhibiting the overexpression of NF- $\kappa$ B p65 and myosin light chain kinase [25]. The effects of berberine on intestinal injury are summarized in Fig. 3.

#### **Ameliorating liver injury**

Animal experiments have shown that the injuries in liver-damaged mice treated with BBR are remarkably ameliorated (Fig. 4). The protective effect is due to BBR interfering with the activation of purinergic receptor P2X7




**Fig. 3** Effects of berberine on intestinal injury.

and suppressing the activation of the NLRP3 inflammasome pathway [26]. Berberine inhibits the phosphorylation state of JNK1 and the production of proinflammatory cytokines in liver and adipose tissue to decrease inflammation and improve hepatic steatosis [27]. BBR attenuates the oxidative damage and hepatotoxicity caused by tert-butyl hydroperoxide by quenching free radicals and inhibiting the loss of glutathione [28]. Experiments showed that BBR significantly ameliorates acetaminophen hepatotoxicity. BBR inhibits inflammation, oxidative stress, and necrosis in injury liver [29], and it also prevents mitochondrial content and biogenesis [30]. In addition, it improves intestinal dysbacteriosis to decrease hepatotoxicity induced by dextran sulfate sodium (DSS) [31]. Hepatic steatosis is attenuated by BBR treatment in a mouse model. The mechanism shows that BBR can induce hepatocyte autophagy, activate FGF21, inhibit lipid accumulation, and increase energy expenditure [32]. The protective properties


of BBR on hepatic steatosis will be further explained in the Section of “Berberine and cancer.”

**Inhibiting *Helicobacter pylori***

BBR exerts antibacterial effects, particularly on *Helicobacter pylori* [33] (Fig. 5). Bae found in his experiment that BBR has a potent inhibitory effect on the growth of *H. pylori* [34], which is associated with the inhibition of arylamine N-acetyltransferase activity in *H. pylori* [35]. BBR inhibits urease activity and urease maturation by targeting the urease active site sulfhydryl group to elicit anti-*H. pylori* effects [36]. Evidence from a clinical trial suggests that BBR combined with triple therapy can be an option to eradicate *H. pylori* [37]. BBR decreases hefA mRNA expression; thus, the minimum inhibitory concentrations of amoxicillin and tetracycline against some *H. pylori* strains have been reduced significantly [38]. BBR



**Fig. 4** Effects of berberine on liver injury.



**Fig. 5** Effects of berberine on *Helicobacter pylori*.

shows killing effects on multidrug-resistant *H. pylori* strains [38]. The anti-*H. pylori* effect has been further demonstrated in an open-label, randomized trial [39]. Moreover, the gastric mucosal inflammation induced by HP lipopolysaccharide (LPS) can be attenuated with BBR treatment because BBR inhibits apoptosis and suppresses the inflammatory response in epithelial cells accompanied by decreased TNF- $\alpha$  and NOS-2 [40]. BBR also inhibits the production of B cell-activating factor (BAFF); therefore, the BAFF-triggered Th17 response is decreased, and the inflammation in *H. pylori*-infected mice with chronic gastritis is attenuated [41].

## Berberine and cancer

### Anti-proliferation

#### *Inducing cell cycle arrest*

Kuo demonstrated that BBR has antitumor activities that can promote apoptosis in human leukemic HL-60 cells. BBR complexes with DNA and cell cycle arrest have been observed in BBR-induced apoptotic HL-60 cells [42]. BBR induces cell cycle arrest at the G<sub>0</sub>/G<sub>1</sub> phase by upregulating proteins Cip/p21 and Kip/p27 and downregulating cyclins D1, D2, and E and cyclin-dependent kinases Cdk2, Cdk4, and Cdk6 [43,44]. With BBR treatment, the cell cycle is mainly arrested at the G<sub>0</sub>/G<sub>1</sub> phase [45–48], and the cell populations at S and G<sub>2</sub>/M are decreased [46]. In addition, BBR enhances the sensitivity of non-small cell lung cancer (NSCLC) A549 cells to ionizing radiation by inducing G<sub>2</sub>/M arrest [49]. BBR can increase the protein expression of the cell cycle inhibitors p53 and p21 to arrest the cell cycle [47].

#### *Inhibiting telomerase*

BBR can downregulate telomerase activity, and telomerase inhibition plays an important role in the proapoptotic effect in HL-60 cells [50]. BBR can bind with various G-quadruplex DNA structures selectively and inhibit telomerase activity effectively [51]. BBR contains natural, flexible cyclic molecules that show a high affinity with the quartets of G-quadruplex structures [52]. Recently, the mechanism of BBR binding with the human telomeric G4 (d[AG<sub>3</sub>(T<sub>2</sub>AG<sub>3</sub>)<sub>3</sub>]) has been further elucidated by FM simulation, and results have shown that BBR has a significant potential to control the mitotic clock and proliferation of cancer cells [53].

#### *Inducing mitochondria-mediated apoptosis*

BBR promotes the mitochondria-dependent pathway to

induce apoptosis in human hepatoma HepG2 cells and human epidermoid carcinoma A431 cells. BBR stimulates the activation of caspase 8 and caspase 3 and induces the cleavage of poly ADP-ribose polymerase (PARP) and loss of mitochondrial membrane potential [54]. BBR upregulates the proapoptotic protein Bax and downregulates the suppression of the antiapoptotic proteins Bcl-2 and Bcl-x [43,54]. It can also enhance the lethal effect of the PARP inhibitor niraparib to promote apoptosis [55]. BBR significantly induces the mRNA expression of FoxO1 and FoxO3a and prevents their degradation. Therefore, BBR upregulates the transcriptional activity of FoxO, which is associated with the antiproliferation of tumors. Increasing FoxO transcription factors strongly induces the expression of the BH3-only protein Bim and activates the proapoptotic protein Bax and caspases, resulting in mitochondria-mediated apoptosis [56]. The BBR-induced overexpression of FoxO3a in apoptotic human lung adenocarcinoma cells is due to the activation of p38 $\alpha$  MAPK [47].

#### *Inducing p53-dependent apoptosis*

BBR downregulates nucleophosmin/B23 at the mRNA and protein levels, which is related to the proapoptotic effect in HL-60 cells [50]. BBR enhances p53 activity by promoting MDM2 self-ubiquitination and degradation. In addition, BBR upregulates the expression levels of p21, PUMA, and Bax [57]. Experiments in human lung adenocarcinoma cells documented that BBR activates p53 and induces apoptosis by activating p38 $\alpha$  MAPK [47]. BBR inhibits DAXX transcription by competitively binding to the consensus sequences of the transcription factors Sp1 and Ets1 to inhibit MDM2 expression. Consequently, p53-dependent apoptosis is induced by BBR through the suppression of MDM2 [58].

#### *Inducing reactive oxygen species (ROS)-mediated mechanisms*

Hsu has documented that BBR exerts an apoptotic effect on SW620 human colonic carcinoma cells by inducing intracellular ROS production and increasing p38 MAPK and JNK activity. BBR induces cytochrome C in the cytosol and PARP cleavage and increases the levels of FasL, c-jun, and t-BID. BBR may promote the generation of ROS in a Fas-FADD-dependent manner and activate caspase-8 and caspase-9 to induce apoptosis [59]. It also induces Ca<sup>2+</sup> production, suppresses the levels of mitochondrial membrane potential, and promotes cytochrome C release and caspase 3 activity in human oral squamous cell carcinoma cancer HSC-3 cells [45]. BBR upregulates ROS generation and lipid peroxidation accompanied by suppression of the activities of superoxide dismutase and

catalase and glutathione levels through activation of the JUK pathway [56]. BBR induces oxidative stress and DNA damage, downregulates RAD51, and damages homologous recombination repair [55].

#### *Inducing mitophagy-dependent necroptosis*

MYC overexpression enhances the transcriptional activity of phosphate cytidyltransferase 1 choline- $\alpha$  (PCYT1A) through the binding site, and PCYT1A increases cellular choline and its phosphorylated derivatives by regulating the choline metabolic pathway and then promotes necroptosis by activating LC3A/B and MLKL in diffuse large B cell lymphoma. BBR inhibits the proliferation of B-lymphoma cells by promoting PCYT1A mRNA degradation and inducing mitophagy-dependent necroptosis [60].

#### *Inhibiting inflammatory cytokines*

BBR inhibits the proliferation of oral cancer cells through an anti-inflammatory pathway. BBR reduces prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) production and inhibits COX<sub>2</sub> expression by inhibiting AP-1 binding in human oral epidermoid carcinoma cell lines [61]. BBR suppresses the activities of NF- $\kappa$ B, IKK, ERK, JNK, and AP-1 and inhibits SCC-4 cell growth through the ERK/MAPK and NF- $\kappa$ B pathways [62]. The anticancer cytokines IFN- $\beta$  and TNF- $\alpha$  can be upregulated by BBR in the breast cancer cell line MCF-7 (estrogen receptor positive) [46]. BBR can modify the Cys179 residue to suppress IKK- $\beta$  activity and inhibit TNF- $\alpha$ -induced I $\kappa$ B $\beta$  kinase activation, consequently suppressing the phosphorylation of p65 and promoting apoptosis [63]. BBR blocks IL-6 and TNF- $\alpha$  to inhibit inflammatory response-driven EGFR-ERK signaling and exerts an antitumor effect on colitis-associated colorectal cancer [64].

#### *Other mechanisms*

In glioblastoma cells, BBR induces senescence against proliferation, which is involved in the downregulation of EGFR and the inhibition of the EGFR–MEK–ERK signaling pathway [48]. However, some studies have shown that BBR has anti-aging properties, promoting AMPK activities to improve autophagic flux and restoring NAD<sup>+</sup> levels to prevent the development of oxidative stress-induced senescence [65]. BBR is also regarded as a novel retinoid X receptor  $\alpha$  (RXR $\alpha$ ) activator that binds RXR $\alpha$ , specifically promoting the degradation of  $\beta$ -catenin and inhibiting the growth of colon cancer cells via  $\beta$ -catenin signaling [66]. The mechanism underlying the anticancer properties of BBR in prostate cancer decreases androgen receptor (AR) transcriptional activity and

promotes AR protein degradation through the disruption of AR–Hsp90 interactions [67]. BBR also regulates microRNAs to exert anticancer effects in biological processes, such as tumorigenesis, proliferation, and differentiation in various malignant diseases [68].

#### **Anti-invasion and antimetastasis**


The levels of fibronectin (FN) and VGFR are increased by TPA by activating the PI3K/AKT-dependent pathway. BBR inhibits VGFR expression to decrease TPA-induced FN and shows an antimetastatic effect on breast cancer cells [69]. BBR upregulates the expression of E-cadherin, downregulates the expression of vimentin and transcription factors Snail1 and Slug, and further inhibits the TGF- $\beta$ 1-induced epithelial-to-mesenchymal transition to prevent lung cancer invasion and metastasis [70].

BBR can also suppress NF- $\kappa$ B, IKK, ERK, and JNK and inhibit SCC-4 cell growth and metastasis by inhibiting the ERK/MAPK and NF- $\kappa$ B pathways [62]. BBR has potential antimigration properties in human gastric adenocarcinoma RF-1 and RF-48 cell lines. It decreases the transcriptional activity of COX<sub>2</sub>, further regulates the gene expression of NF- $\kappa$ B/p65, and induces cancer apoptotic cell death [71]. BBR activates AMPK activities to suppress ERK activity and COX<sub>2</sub> protein expression inhibiting A375 human melanoma cell metastasis [72]. BBR also reduces the levels of matrix metalloproteinase (MMP)-1, -2, and -7, which are related to the induction of ROS, resulting in an antimigration effect in the human gastric cancer SNU-5 cell line [73]. BBR reduces the levels of MMP-2 and MMP-9, which contribute to metastasis, in SCC-4 cells [62], human gastric adenocarcinoma RF-1 and RF-48 cell lines [71], and triple negative breast cancer cells [74]. BBR also decreases the level of uPA in SCC-4 cells [62]. BBR effectively inhibits tumor proliferation and lymphatic metastasis in Lewis lung carcinoma cells by repressing AP-1 transcriptional activity and u-PA expression. In addition, BBR suppresses the migration and invasion of triple-negative breast cancer cells by inhibiting TGF- $\beta$ 1 and downregulating Smads [74]. BBR inhibits the intracranial invasion of nasopharyngeal carcinoma (NPC) by suppressing nasopharyngeal carcinoma cell viability and migration through NM23-H1 expression upregulation. BBR also significantly decreases the current value of I<sub>CRAC</sub> in 5-8F nasopharyngeal cancer cells [75].

In addition, in NPC cells, BBR inhibits Ezrin phosphorylation mediated by Rho kinase to reduce cell motility and inhibit tumor metastasis [76]. The antitumor effects of berberine are shown in Fig. 6, Table 1, and Table 2.

#### **Effects on chemoradiotherapies**

Combined radiation therapy with BBR can enhance cytotoxicity in lung cancer A549 cells *in vivo* and *in*



**Fig. 6** Effects of berberine on cancer proliferation, invasion, and metastasis.

*vitro*. BBR can increase radiosensitivity via autophagy [49]. Another experiment on esophageal squamous cell carcinoma demonstrated that the underlying mechanisms are that BBR inhibits HIF-1 $\alpha$  and VEGF expression and significantly decreases hypoxic activity. This result suggests that BBR can be used as a potential radiotherapy sensitization drug [77]. BBR cannot only enhance radiosensitivity but also increase chemosensitivity. BBR at a low dose can increase chemosensitivity to doxorubicin (DOX) in MCF-7 breast cancer cells that have been cultured under hypoxic conditions to elicit resistance. The mechanisms further indicate that BBR can suppress the protein expression of AMPK and HIF-1 $\alpha$ . Increasing the concentration of BBR activates P53 and induces apoptosis directly [78]. BBR sensitizes human ovarian cells to the anticancer effect of cisplatin by downregulating miR-93 and inhibiting the PTEN/Akt pathway [79]. The synergistic cytotoxic effect of CPT-11 and BBR is significantly enhanced, which leads to inhibition of tumor proliferation and lymphatic metastasis in Lewis lung carcinoma cells. These results suggest that BBR represses AP-1 transcriptional activity and u-PA expression [80]. BBR possesses a significant cytotoxic effect on gefitinib-resistant NSCLC cells by inhibiting sterol regulatory element binding protein 1 activity and suppressing lipogenesis. This effect occurs because BBR strongly suppresses the activity of

complex I in the mitochondrial respiratory chain, reduces ATP, and stimulates the ROS/AMPK pathway [81]. In addition, the repopulation of ovarian cancer cells triggered by the chemotherapy drug VP16 is suppressed by the inhibition of the arachidonic acid pathway through the BBR-mediated inhibition of iPLA2 and COX<sub>2</sub> expression. In addition, BBR decreases the PEG<sub>2</sub> level and suppresses the phosphorylation of FAK, which contributes to the inhibition of repopulation of ovarian cancer cells [82].

## Berberine and metabolic disorder

### Berberine and glycometabolism

BBR increases glucose and 2-deoxyglucose uptake in myotubes and adipocytes to enhance glucose utilization [83]. It facilitates glucose uptake in 3T3-L1 adipocytes through a mechanism that is distinct from insulin signaling and does not increase glucose transport 4 (GLUT4) expression. However, BBR increases glucose transport 1 activities, which may be associated with the increased phosphorylation of AMPK and ACC in 3T3-L1 adipocytes [84]. BBR increases the phosphorylation of the endogenous substrate AS160 to facilitate GLUT4 translocation and enhances 3-O-methyl-D-glucose transport. AMPK activity

**Table 1** Antiproliferation effect of berberine

Origin	Cell line	Effect of berberine	Mechanism	Experiment model	Year	Authors
Human leukemia	HL-60	Antiproliferation, induces apoptosis and cell cycle arrest	Complexes with DNA	<i>In vitro</i>	1995	Kuo <i>et al.</i> [42]
Human leukemia	HL-60	Antiproliferation, induces apoptosis	Downregulates nucleophosmin/B23 and telomerase activity	<i>In vitro</i>	1999	Wu <i>et al.</i> [50]
Human leukemia	U937	Antiproliferation	Inhibits telomerase activity	<i>In vitro</i>	1999	Wu <i>et al.</i> [50]
Oral cancer	OC2, KB	Antiproliferation	Reduces AP-1 expression, inhibits COX-2 protein	<i>In vitro</i> and <i>in vivo</i>	2004	Kuo <i>et al.</i> [61]
Human breast cancer	MCF-7	Antiproliferation, induces apoptosis and G <sub>0</sub> /G <sub>1</sub> arrest	Upregulates interferon- $\beta$ and TNF- $\alpha$	<i>In vitro</i>	2005	Kang <i>et al.</i> [46]
Human hepatoma	HepG2	Antiproliferation, induces apoptosis	Activates caspases 8, caspases 3 and PARP	<i>In vitro</i>	2006	Hwang [54]
Human epidermoid carcinoma	A431	Antiproliferation, induces G <sub>1</sub> arrest and apoptosis	Upregulates Cip/p21 and Kip/p27 protein, disrupts mitochondrial membrane potential, activates caspase 3 and PARP	<i>In vitro</i>	2006	Mantena <i>et al.</i> [44]
Human oral squamous carcinoma cancer	HSC-3	Antiproliferation, induces cell cycle arrest and apoptosis	Induces ROS and Ca <sup>2+</sup> production, suppresses the levels of mitochondrial membrane potential (MMP)	<i>In vitro</i>	2007	Lin <i>et al.</i> [45]
Human colonic carcinoma	SW620	Antiproliferation, induces apoptosis	Generates reactive oxygen species and activates JNK/p38 MAPK and FasL	<i>In vitro</i>	2007	Hsu <i>et al.</i> [59]
Non-small cell lung cancer	A549	Induce autophagy, enhances radio-sensitivity	Induces autophagy	<i>In vitro</i> and <i>in vivo</i>	2008	Peng <i>et al.</i> [49]
Human leukemia	Jurkat	Antiproliferation, induces apoptosis	Modifies cysteine 179 of I $\kappa$ B $\alpha$ kinase, suppresses nuclear factor- $\kappa$ B-regulated antiapoptotic gene products	<i>In vitro</i>	2008	Pandey <i>et al.</i> [63]
Acute lymphoblastic leukemia	EU-1, Sup-B13	Antiproliferation, induces apoptosis	Downregulates DAXX expression and promotes MDM2 degradation	<i>In vitro</i>	2010	Zhang <i>et al.</i> [57]
Prostate cancer	LNCaP	Antiproliferation	Suppresses androgen receptor	<i>In vitro</i> and <i>in vivo</i>	2011	Li <i>et al.</i> [67]
Human breast cancer	MCF7, T47D	Antiproliferation	Suppresses TPA-induced VEGF and fibronectin	<i>In vitro</i>	2013	Kim <i>et al.</i> [69]
Esophageal squamous cell carcinoma	ECA109, TE13	Induces autophagy, enhances radio-sensitivity	Decreases hypoxic activity	<i>In vitro</i> and <i>in vivo</i> (ECA109)	2013	Yang <i>et al.</i> [77]
Human neuroblastoma	SK-N-SH, NB-1691	Antiproliferation, induces apoptosis	Inhibits the transcription of DAXX	<i>In vitro</i>	2013	Li <i>et al.</i> [58]
Human lung adenocarcinoma	A549	Induces apoptosis and G <sub>0</sub> /G <sub>1</sub> arrest	Induces FOXO3a and p53, activates p38 $\alpha$ MAPK	<i>In vitro</i>	2014	Zheng <i>et al.</i> [47]
Human ovarian	A2780	Sensitizes the effect of cisplatin	Downregulates miR-93 and inhibits the PTEN/Akt pathway	<i>In vitro</i>	2015	Chen <i>et al.</i> [79]
Human glioblastoma	U87, U251	Antiproliferation, induce senescence	Downregulates EGFR and inhibits the EGFR-MEK-ERK signaling pathway	<i>In vitro</i> and <i>in vivo</i> (U87)	2015	Liu <i>et al.</i> [48]
Colon cancer	KM12C	Antiproliferation	Binds RXR $\alpha$ to suppress $\beta$ -catenin signaling	<i>In vitro</i> and <i>in vivo</i>	2017	Ruan <i>et al.</i> [66]
Diffuse large B cell lymphoma	HEK-293T	Antiproliferation, impedes mitophagy-dependent necroptosis, induces mitophagy-dependent necroptosis	Accelerates PCYT1A mRNA degradation and inhibits the MYC-driven aberration of choline metabolism	<i>In vitro</i> and <i>in vivo</i>	2017	Xiong <i>et al.</i> [60]
Ovarian cancer	A2780, HO8910	Antiproliferation, increases sensitivity to PARP inhibition, homologous recombination repair	Induces oxidative DNA damage and impairs homologous recombination repair	<i>In vitro</i> and <i>in vivo</i> (A2780)	2017	Hou <i>et al.</i> [55]
Breast cancer cell	MCF-7	Reverses resistance to doxorubicin	Inhibits AMPK-HIF-1 $\alpha$	<i>In vitro</i> and <i>in vivo</i>	2017	Pan <i>et al.</i> [78]

(Continued)

Origin	Cell line	Effect of berberine	Mechanism	Experiment model	Year	Authors
Colon intestinal	IMCE	Antitumorigenesis	Block IL-6 and TNF- $\alpha$ , inhibits EGFR-ERK signaling	<i>In vitro</i> and <i>in vivo</i>	2017	Li <i>et al.</i> [64]
Ovarian cancer	SKOV3	Antiproliferation	Suppresses the arachidonic acid metabolic pathway and phosphorylation of FAK	<i>In vitro</i>	2017	Zhao <i>et al.</i> [82]
Gefitinib-resistant non-small cell lung cancer	H1975	Antiproliferation, suppression of lipogenesis	Induces reactive oxygen species generation and activates the AMPK pathway	<i>In vitro</i>	2018	Fan <i>et al.</i> [81]

**Table 2** Anti-invasive and antimetastatic effects of berberine

Origin	Cell line	Effect of berberine	Mechanism	Experiment model	Year	Authors
Lewis lung carcinoma	Lewis lung carcinoma	Antiproliferation, antimetastasis	Represses AP-1 transcriptional activity and u-PA expression	<i>In vitro</i> and <i>in vivo</i>	2001	Mitani <i>et al.</i> [80]
Human gastric adenocarcinoma	RF-1, RF-48	Antimetastasis	Decreases the expression of COX-2, MMP-2, and MMP-9	<i>In vitro</i>	2006	Yu <i>et al.</i> [71]
Human gastric cancer	SNU-5	Antimetastasis	Downregulates the expression of matrix metalloproteinases-1, -2, and -7	<i>In vitro</i>	2006	Lin <i>et al.</i> [73]
Nasopharyngeal carcinoma	5-8F	Anti-invasion	Downregulates NM23-H1 expression	<i>In vitro</i> and <i>in vivo</i>	2008	Liu <i>et al.</i> [75]
Human tongue squamous cancer	SCC-4	Antimetastasis, anti-invasion	Inhibits FAK, IKK, NF- $\kappa$ B, u-PA and MMP-2 and MMP-9	<i>In vitro</i>	2009	Ho <i>et al.</i> [62]
Nasopharyngeal carcinoma	5-8F	Antimetastasis	Inhibits Ezrin phosphorylation	<i>In vitro</i> and <i>in vivo</i>	2009	Tang <i>et al.</i> [76]
Human melanoma	A375	Antimetastasis	Reduces ERK activity and COX-2, induces AMPK activation	<i>In vitro</i>	2012	Kim <i>et al.</i> [72]
Non-small cell lung cancer	A549	Antiproliferation, antimetastasis	Inhibits TGF- $\beta$ 1-induced epithelial-to-mesenchymal transition	<i>In vitro</i> and <i>in vivo</i>	2014	Qi <i>et al.</i> [70]
Triple-negative breast cancer	MDA-MB231	Anti-invasion	Downregulates TGF- $\beta$ 1	<i>In vitro</i> and <i>in vivo</i>	2018	Kim <i>et al.</i> [74]

is stimulated by BBR, and the intracellular energy status in skeletal muscle is reduced [85]. BBR also regulates the expression of metabolic genes, leading to the suppression of lipogenesis and induction of energy expenditure in adipose tissue and muscle [86]. BBR activates protein kinase C (PKC) to increase insulin receptor (InsR) gene expression. It effectively upregulates the transcription of the InsR-dependent PKC/AMPK pathway and improves glucose consumption and insulin sensitivity in a type 2 diabetes mellitus rodent model [87]. A clinical trial also demonstrated that InsR expression is elevated and glucose is lowered in patients with type 2 diabetes mellitus, especially those with liver disease and those treated with

BBR [88]. In addition, BBR can improve insulin sensitivity in adipocytes by inhibiting proinflammatory responses in macrophages. BBR not only downregulates LPS- and TNF-induced proinflammatory responses by inhibiting the MAPK pathway but also suppresses ROS generation by stimulating AMPK activities in macrophages [89]. BBR inhibits aerobic respiration, leading to a reduction in oxygen consumption and the induction of the AMP/ATP ratio, thereby increasing AMPK activity [83]. BBR inhibits mitochondrial respiration in L6 myotubes by inhibiting the mitochondrial respiratory complex I [90]. Although BBR inhibits oxygen consumption in the mitochondria, it does not induce extra cell toxicity through

enhancing anaerobic respiration to compensate for the inhibition of aerobic respiration [83]. BBR activates SIRT1 by increasing the  $\text{NAD}^+/\text{NADH}$  ratio and the expression of nicotinamide phosphoribosyltransferase. SIRT1 plays an indispensable role in the preventive effects of BBR on diet-induced insulin resistance. The effect of BBR on improving insulin sensitivity is partly due to BBR reverting mitochondrial dysfunction and improving hyperglycemia in skeletal muscle through activation of SIRT1-dependent mitochondrial biogenesis [91]. Wang has shown that the oral administration of BBR can downregulate blood lipid and glucose levels through promoting the production of the short chain fatty acid (SCFA) butyrate by the gut microbiota. This result suggests that BBR lowers ATP and NADH levels to regulate the energy metabolism network in the intestinal microbiota to upregulate PTB/BUT enzymes and increase butyrate production [92]. BBR suppresses basal autophagy in mature adipocytes of mice fed a high-fat diet by targeting BECN1. The inhibition of autophagy decreases fatty acid oxidation and increases insulin sensitivity [93]. BBR decreases the expression of peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) and fatty acid transferase and then inhibits fatty acid uptake, eventually improving free fatty acid-induced insulin resistance in L6 myotubes [94].

In addition, BBR can inhibit hepatic gluconeogenesis to increase glucose utilization in peripheral tissues. BBR restricts fatty acid oxidation to decrease acetyl CoA contents and limits pyruvate transport into mitochondria through mitochondrial pyruvate carrier 1 (MPC1). BBR preserves the acetylation of MPC1 and blocks gluconeogenesis [95]. BBR exerts a glucose-lowering effect on hepatocytes, which neither affects insulin secretion nor depends on insulin concentration [96]. However, BBR can restore the diminished insulin secretion in INS-1E cells and in islets from diabetic db/db mice by increasing AMPK

phosphorylation and uncoupling protein-2 (UCP2) expression. Activation of AMPK and UCP2 attenuates oxidative stress and inhibits mitochondrial ROS production in HG-treated rat islets [97]. Moreover, BBR supplementation can normalize the levels of leptin and adiponectin, which contributes to reversing lipid and glucose homeostasis [91]. The effects of berberine on glycometabolism are summarized in Fig. 7.

BBR ameliorates insulin resistance caused by complications in type 2 diabetes mellitus. BBR alleviates mesenteric artery endothelial dysfunction and enhances vascular vasodilation. BBR increases phosphorylated IRs and activates the IR-Akt-eNOS cascade in type 2 diabetes mellitus rodent models [98,99]. BBR also alleviates cerebral arterial contractility by inhibiting  $\text{Ca}_L$  (L-type  $\text{Ca}^{2+}$ ) channel function and  $\text{Ca}^{2+}$  release from the RyRs in cerebral vascular smooth cells (VSMCs) under hyperglycemic conditions in the rat model of streptozotocin-induced diabetes [100]. Oxidative stress and glial fibrillary acidic protein-immunoreactive astrocytes are ameliorated in the hippocampus of diabetic rats because of the beneficial effects of BBR on the reduction of superoxide dismutase (SOD) activity and lipid peroxidation and the regulation of the NO system. BBR exerts a protective effect on central nervous system disorders induced by diabetes mellitus [101].

### Berberine and lipid metabolism

BBR is an effective cholesterol-lowering drug that has been tested in a clinical trial. It reduces serum cholesterol, triglyceride, and low-density lipoprotein cholesterol (LDL-c) without affecting serum high-density lipoprotein cholesterol (HDL-c) levels. According to the experimental results in hepatoma cells, BBR upregulates low-density lipoprotein receptor (LDLR) expression by directly




Fig. 7 Effects of berberine on glycometabolism.

stimulating the ERK signaling pathway to stabilize LDLR mRNA; as a result, LDL-c homeostasis is improved. The mechanism has no relation to the activation of SREBP or the activity of HMGCoA reductase [102]. Therefore, BBR is a nutraceutical considered as an alternative therapy to reduce LDL-c levels in statin-tolerant patients to avoid the statin-associated muscular adverse reaction [103]. BBR also increases the mRNA levels of Luc-UTR transcript and endogenous LDLR mRNA through the LDLR 3' UTR region in the livers of Alb-Luc-UTR mice [104]. BBR can increase the phosphorylation levels of hepatic AMPK and ACC in obese db/db mice to promote fatty acid oxidation, eventually ameliorating hyperlipidemia [105]. BBR exerts an antilipolytic effect mainly by reducing the inhibition of phosphodiesterase by 3T3-L1 adipocytes, leading to the attenuation of cAMP-induced lipolysis [106]. BBR regulates the expression of metabolic genes, suppresses lipogenesis, and induces energy expenditure by activating AMPK activity in adipose tissue and muscle. As a result, body weight is reduced and triglyceride level is decreased [86]. Experiments suggest that BBR can lower blood cholesterol levels, which are associated with the inhibition of intestinal absorption, and decrease cholesterol micellization and cholesterol uptake by enterocytes. In addition, BBR reduces cholesterol esterification and secretion by inhibiting ACAT2 expression and decreases permeability through Caco-2 monolayers [107]. BBR can modulate cholesterol metabolism and bile acid homeostasis to exert a lipid-lowering effect. It suppresses bile salt hydrolase activity and increases the levels of taurocholic acid in the intestine, which activates the intestinal FXR pathway and reduces the expression of the Cd36 gene, thereby reducing the uptake of long-chain fatty acids in the liver. Consequently, obesity is prevented, and triglyceride accumulation is ameliorated [108].

#### *Berberine and obesity*

BBR reduces body weight and increases energy expenditure without a significant effect on food intake in db/db mice [86]. Except for the previously described mechanisms by which BBR mediates lipid metabolism, the antiadipogenic and anti-inflammatory effects of BBR on 3T3-L1 adipocytes contribute to the reduction in adipocytes. BBR inhibits the expression of adipogenic enzymes (fatty acid synthase, acetyl-CoA carboxylase, acyl-CoA synthase, and lipoprotein lipase) and transcription factors (SREBP-1c, C/EBP- $\alpha$ , and PPAR- $\gamma$ ), thereby decreasing the production of adipocytes and the secretion of leptin. BBR downregulates proinflammatory markers, including TNF- $\alpha$ , IL-6, C-reactive protein, and haptoglobin [109]. BBR strongly increases the expression of UCP1 and other classical BAT marker genes to facilitate energy expenditure and thermogenic activities in the BAT of obese db/db mice. The

transcription of UCP1 is increased by BBR treatment through AMPK activation and PGC-1 $\alpha$  recruitment. In addition, BBR contributes to a robust defense against obesity by inducing energy expenditure and adaptive thermogenesis *in vivo* [110]. BBR mitigates body weight gain by shifting the structure of the gut microbiota and reducing microbial diversity in high-fat diet-induced obesity rats. BBR markedly increases SCFA-producing bacteria, including *Allobaculum*, *Bacteroides*, *Blautia*, *Butyrivoccus*, and *Phascolarctobacterium*, which contribute to the amelioration of metabolic abnormalities [111].


#### *Berberine and nonalcoholic fatty liver disease (NAFLD)*

The antihyperlipidemic effect of BBR also improves nonalcoholic fatty liver disease. BBR ameliorates hyperlipidemia and removes excess hepatic fat accumulation by stimulating AMPK activities, and it also improves liver function [105]. BBR suppresses inflammatory signaling and adipose tissue inflammatory responses by reducing the phosphorylation of JUK1 and inflammatory cytokines, including IL-1 $\beta$ , IL-6, and/or TNF- $\alpha$ , in C57BL/6J mice fed a high-fat diet, thereby improving hepatic steatosis [27]. BBR exerts a protective effect on the liver following cholesterol overloading partly by inhibiting hepatic autophagic flux. BBR not only decreases hepatic cholesterol levels and suppresses cholesterol trafficking toward the plasma membrane by decreasing sterol carrier protein 2 but also mitigates the COX<sub>2</sub>-mediated production of prostaglandin metabolites, thereby modulating Akt/mTOR activity [112]. The effects of berberine on lipid metabolism, obesity, and NAFLD are summarized in Fig. 8.

## **Berberine and cardiovascular diseases**

### **Berberine and heart failure**

BBR exhibits hemodynamic improvement in patients with refractory congestive heart failure. BBR has strong positive inotropic and peripheral resistance-lowering effects. It reduces the left ventricular systolic dimension and induces the left ventricular ejection fraction to decrease ventricular pressure. The ventricular filling pressures are decreased by BBR by reducing systemic and pulmonary venous pressures [113]. BBR increases the indices of inotropism. BBR can modify the contractile states of the myocardium with no changes in heart rate [113]. Fbxo32, an antihypertrophic E3 ligase, can be upregulated by BBR to ameliorate pathological hypertrophic remodeling and prevent the development of heart failure in cardiac-deficient Pak1 mice under pressure overload [114]. BBR features muscarinic agonist-like properties, decreases the spontaneous contraction rate, and exerts chronotropic activity in cardiomyocytes of



**Fig. 8** Effects of berberine on lipid metabolism, obesity, and nonalcoholic fatty liver disease.

neonatal mouse cardiomyocytes by activating cardiac  $M_2$  muscarinic cholinergic receptors [115].

### Berberine and arrhythmias

BBR effectively suppresses ischemic ventricular tachyarrhythmias, including ventricular premature contractions (VPCs), paired VPCs, VPCs with R on T, and ventricular tachycardias caused by ligating the left anterior descending coronary artery, in canine models [116]. BBR exerts antiarrhythmic effects on action potential duration (APD) and ionic currents of ventricular myocytes. BBR prolongs APD in ventricular myocytes, and the underlying mechanism is that BBR at concentrations of 0.3–30  $\mu\text{mol/L}$  can selectively block the rapid current ( $I_{Kr}$ ) in the outward delayed rectifier potassium current ( $I_K$ ). At concentrations higher than 10  $\mu\text{mol/L}$ , BBR exerts an inhibitory effect on the transient outward ( $I_{to1}$ ) current [117]. Experiments in *Xenopus* oocytes have documented that BBR not only inhibits  $I_K$  and inward rectifier potassium current ( $I_{K1}$ ) in a concentration-dependent manner but also produces a voltage-dependent block of HERG channels; as a result, depolarization is significantly increased, and APD is prolonged [118]. In addition, BBR can upregulate Kir2.1 channel protein expression, restore  $I_{K1}$  potassium current and current density [119], recover the diminished  $I_{to}$  and  $I_{Ca}$  current densities, restore the prolonged QTc interval [120], and stabilize resting membrane potential [119] to show antiarrhythmic effects in a rat model of diabetes mellitus with myocardial infarction.

### Berberine and atherosclerosis

BBR has antihypercholesterolemic efficacy. It reduces the levels of total cholesterol, triglycerides, and LDL cholesterol; increases HDL cholesterol [121]; and improves the

leptin-to-adiponectin ratio [122] in patients with a risk of cardiovascular disease. Clinical evidence suggests that BBR–silymarin association exerts a strong effect on the improvement of lipid and glucose metabolism and possibly promotes cardiovascular health. Silymarin not only increases BBR oral bioavailability but also reduces gastrointestinal discomfort [123]. BBR exerts protective pharmacological properties against hyperglycemia-induced cellular injury and endothelial dysfunction. It can ameliorate hyperglycemia-induced endothelial injury and enhance endothelium-dependent vasodilatations by activating the AMPK signaling pathway and inducing eNO production [124]. BBR is potentially efficacious in reducing cardiometabolic disease risk and improving cardiovascular diseases. It regulates lipid profile and blood pressure, improves hypercholesterolemia and hypertension, inhibits the inflammation of vascular endothelium, and enhances endothelial function [125–127]. The beneficial effects of BBR can attenuate the development of atherosclerosis. Given its protective effect on cardiovascular disease and lipid metabolism, BBR is considered a potentially beneficial complement to menopausal women to relieve their discomfort and improve quality of life [128].

### Berberine and ischemic heart disease

BBR shows protective properties against myocardial ischemia/reperfusion injury through antioxidative and anti-inflammatory effects. It attenuates apoptosis, increases SOD level, decreases infarct size, and diminishes serum creatine kinase and lactate dehydrogenase levels, which are associated with activation of SIRT1 signaling [129]. Experiments in rat H9c2 myocytes confirmed that BBR can ameliorate hypoxia/reoxygenation injury by decreasing the level of autophagy. It downregulates the expression

of the autophagy-related proteins SIRT1, BNIP3, and Beclin-1 and inhibits AMPK-mTOR pathway activities [130]. BBR also ameliorates the increase in cardiac output of ischemic ventricular disease [116].

### **Berberine and hypertension**

BBR demonstrates relaxant and anticonstrictive effects on the isolated thoracic aortas of rats in a dose-dependent manner. BBR exerts hypotensive effect partly by inhibiting angiotensin-converting enzyme activities and inducing the release of NO and cGMP production directly in vascular tissues [131,132]. BBR significantly reduces the expression of oxidized LDL (oxLDL) and TNF- $\alpha$ -induced lectin-like oxLDL receptor 1 and inhibits oxidative stress by reducing intracellular ROS levels to protect endothelial cells and improve endothelium-mediated vasodilatation [133]. A clinical trial proved that BBR can effectively decrease the mean 24-h systolic and 24-h pulse pressures in patients [134]. BBR can improve vascular stiffness and antivasular aging to decrease the mean BP and pulse BP through the blockade of transient receptor potential vanilloid 4 channels, reduction in intracellular Ca<sup>2+</sup> levels in VSMCs, and induction of vasorelaxation [135]. In addition, BBR can alleviate the effect of norepinephrine (NE) to improve pulmonary arterial hypertension by suppressing protein phosphatase 2A signaling pathways [136].

### **Berberine and other cardiovascular diseases**

BBR can dramatically attenuate the impairment of cardiac function and pathophysiological severity and decrease antiscardiac myosin antibody levels to ameliorate myosin-induced myocardial injury in experimental autoimmune myocarditis rats. BBR exerts a protective effect by suppressing Th17 and Th1 cell differentiation and reversing the increased response of Th17/Th1 cells through blocking p-STAT1, p-STAT3, and p-STAT4 activities [137]. BBR ameliorates the cardiotoxicity caused by anthracycline DOX by upregulating Sirt3 and Sirt1 protein expression to restore the increase in mitochondrial-mediated apoptosis and oxidative stress, promote mitophagy, and induce mitochondrial biogenesis [138]. The effects of berberine on cardiovascular diseases are summarized in Fig. 9.

### **Berberine and neurological diseases**

BBR has potent neuroprotective properties. At low concentrations, BBR significantly attenuates 6-OHDA-induced cytotoxicity to protect PC12 cells and zebrafish

from further damage through the activation of hormetic mechanisms, which are activated by the induction of PI3K/AKT/Bcl-2 cell survival and Nrf2/HO-1 antioxidative signaling pathways. However, the neuroprotective activities of BBR at high concentrations are minimal [139]. BBR effectively protects spiral ganglion cells from damage through its antiapoptotic and antioxidative properties. At low concentrations, BBR can decrease apoptosis induced by *Cytomegalovirus* in cultured spiral ganglion cells by suppressing NMDAR1/Nox3; therefore, mitochondrial ROS generation is significantly reduced [140]. BBR also shows a protective effect on ischemia-reperfusion injury of the brains of mice subjected to transient middle cerebral artery occlusion. The underlying pathogenesis has been elucidated: BBR impedes the release of HMGB1 and inhibits NF- $\kappa$ B nuclear translocation, consequently suppressing HMGB1/TLR4/NF- $\kappa$ B signaling [141]. BBR has protective abilities against ischemic brain damage in rats partly by blocking outward potassium current (I<sub>A</sub>) and delaying rectifier potassium current (I<sub>K</sub>) in acutely isolated CA1 pyramidal neurons from rat hippocampi [142]. BBR demonstrates potential antidepressant-like actions. BBR is a substrate and an inhibitor of organic cation transporter 2 and transporter 3, which are low-affinity and high-capacity transporters (uptake-2), respectively. Studies on transfected MDCK cells have documented that BBR can increase serotonin/NE/dopamine (5-HT/NE/DA) levels by inhibiting OCT2- and OCT3-mediated 5-HT and NE uptake, leading to enhanced monoamine neurotransmission in mouse brains [143]. BBR enhances 5-HT<sub>2</sub> receptor activation partly by influencing the BDNF-eEF2 pathway in the hippocampus and CREB signaling in the frontal cortex [144]. In stress mouse models, BBR inhibits the proinflammatory cytokines IL-6 and TNF- $\alpha$ , decreases the activation of microglia, and inhibits the NF- $\kappa$ B pathway in the hippocampus to show antidepressant-like effects [145].

### **Berberine and other diseases**

BBR exerts protective effects on kidney tissues against aldosterone-induced podocyte injury. It can suppress aldosterone-induced oxidative stress and endoplasmic reticulum stress and improve the podocyte injury and extensive fusion of foot processes [146]. BBR relieves edema and pain in monoarthritic rats by selectively decreasing JAK3 phosphorylation through binding to the kinase domain of JAK3, consequently suppressing inflammation in the synovial tissues of rat joints [147]. BBR promotes osteoblast differentiation to accelerate osteogenesis by activating Runx2 and increasing COX<sub>2</sub> expression [148]. Studies have confirmed that BBR can suppress the propagation of ZIKV in both murine and human testes [149].




Fig. 9 Effects of berberine on cardiovascular diseases.

## Conclusions

Cancer and cardiovascular, metabolic, and neurological diseases are chronic illnesses that require long-term, ongoing management. In the course of medical treatment, many challenges emerge, such as resistance, adverse drug reactions, and serious concomitant symptoms. BBR is a safe and effective natural product that is used in various diseases and pathological conditions; thus, it is a potential choice for long-term treatment and management. Recently, a serious challenge in anticancer therapy is multidrug resistance (MDR), and overcoming MDR is a major goal that requires enormous efforts to achieve. BBR not only inhibits the proliferation, invasion, and metastasis of cancer but also enhances the effects of chemoradiotherapies. It is a promising drug with few adverse reactions, which may offer an exciting therapeutic option to solve the problem. In addition, the cancer risk in diabetic patients increases slightly, and cancer mortality increases. Therefore, BBR stands out for its wide range of pharmacological effects that are beneficial to cancer and metabolic disorders. Furthermore, BBR is expected to be appropriate for patients suffering from more than one disease, considering the strong association among metabolic, cardiovascular, and neurological diseases. In this article, we explained the properties of BBR and its mechanisms, and most data were obtained from preclinical experiments; the clinical trials have not been extensively carried out. Therefore, evidence from clinical investigations is insufficient, and further clinical research should be conducted in the future.

## Acknowledgements

The author thanks the Xinjuan Liu from the Department of Gastroenterology, Beijing Chaoyang Hospital for the help.

## Compliance with ethics guidelines

Danyang Song, Jianyu Hao, and Daiming Fan declare that they have no conflict of interest. This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

## References

1. Yarla NS, Bishayee A, Sethi G, Reddanna P, Kalle AM, Dhananjaya BL, Dowluru KS, Chintala R, Duddukuri GR. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. *Semin Cancer Biol* 2016; 40-41: 48–81
2. Hesari A, Ghasemi F, Cicero AFG, Mohajeri M, Rezaei O, Hayat SMG, Sahebkar A. Berberine: a potential adjunct for the treatment of gastrointestinal cancers? *J Cell Biochem* 2018; 119(12): 9655–9663
3. Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from *in vitro* evidence to clinical studies. *Atherosclerosis* 2015; 243(2): 449–461
4. Subbaiah TV, Amin AH. Effect of berberine sulphate on *Entamoeba histolytica*. *Nature* 1967; 215(5100): 527–528
5. Amin AH, Subbaiah TV, Abbasi KM. Berberine sulfate: antimicrobial activity, bioassay, and mode of action. *Can J Microbiol* 1969; 15(9): 1067–1076
6. Dutta NK, Marker PH, Rao NR. Berberine in toxin-induced

- experimental cholera. *Br J Pharmacol* 1972; 44(1): 153–159
7. Wang S, Setlow B, Setlow P, Li YQ. Uptake and levels of the antibiotic berberine in individual dormant and germinating *Clostridium difficile* and *Bacillus cereus* spores as measured by laser tweezers Raman spectroscopy. *J Antimicrob Chemother* 2016; 71(6): 1540–1546
  8. Li Y, Huang J, Li L, Liu L. Synergistic activity of berberine with azithromycin against *Pseudomonas aeruginosa* isolated from patients with cystic fibrosis of lung *in vitro* and *in vivo*. *Cell Physiol Biochem* 2017; 42(4): 1657–1669
  9. Sack RB, Froehlich JL. Berberine inhibits intestinal secretory response of *Vibrio cholerae* and *Escherichia coli* enterotoxins. *Infect Immun* 1982; 35(2): 471–475
  10. Wen SQ, Jeyakkumar P, Avula SR, Zhang L, Zhou CH. Discovery of novel berberine imidazoles as safe antimicrobial agents by down regulating ROS generation. *Bioorg Med Chem Lett* 2016; 26(12): 2768–2773
  11. Liu X, Zhang N, Liu Y, Liu L, Zeng Q, Yin M, Wang Y, Song D, Deng H. MPB, a novel berberine derivative, enhances lysosomal and bactericidal properties via TGF- $\beta$ -activated kinase 1-dependent activating the transcription factor EB. *FASEB J* 2019; 33(1): 1468–1481
  12. Eaker EY, Sninsky CA. Effect of berberine on myoelectric activity and transit of the small intestine in rats. *Gastroenterology* 1989; 96(6): 1506–1513
  13. Taylor CT, Baird AW. Berberine inhibition of electrogenic ion transport in rat colon. *Br J Pharmacol* 1995; 116(6): 2667–2672
  14. Rabbani GH, Butler T, Knight J, Sanyal SC, Alam K. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic *Escherichia coli* and *Vibrio cholerae*. *J Infect Dis* 1987; 155(5): 979–984
  15. Watanabe-Fukuda Y, Yamamoto M, Miura N, Fukutake M, Ishige A, Yamaguchi R, Nagasaki M, Saito A, Imoto S, Miyano S, Takeda J, Watanabe K. Orengeodokuto and berberine improve indomethacin-induced small intestinal injury via adenosine. *J Gastroenterol* 2009; 44(5): 380–389
  16. Liu Y, Liu X, Hua W, Wei Q, Fang X, Zhao Z, Ge C, Liu C, Chen C, Tao Y, Zhu Y. Berberine inhibits macrophage M1 polarization via AKT1/SOCS1/NF- $\kappa$ B signaling pathway to protect against DSS-induced colitis. *Int Immunopharmacol* 2018; 57: 121–131
  17. Hering NA, Fromm M, Schulzke JD. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. *J Physiol* 2012; 590(5): 1035–1044
  18. Li GH, Zhang YP, Tang JL, Chen ZT, Hu YD, Wei H, Li DZ, Hao P, Wang DL. Effects of berberine against radiation-induced intestinal injury in mice. *Int J Radiat Oncol Biol Phys* 2010; 77(5): 1536–1544
  19. Yan F, Wang L, Shi Y, Cao H, Liu L, Washington MK, Chaturvedi R, Israel DA, Cao H, Wang B, Peek RM Jr, Wilson KT, Polk DB. Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. *Am J Physiol Gastrointest Liver Physiol* 2012; 302(5): G504–G514
  20. Li C, Xi Y, Li S, Zhao Q, Cheng W, Wang Z, Zhong J, Niu X, Chen G. Berberine ameliorates TNBS induced colitis by inhibiting inflammatory responses and Th1/Th17 differentiation. *Mol Immunol* 2015; 67(2 Pt B): 444–454
  21. Guo BJ, Bian ZX, Qiu HC, Wang YT, Wang Y. Biological and clinical implications of herbal medicine and natural products for the treatment of inflammatory bowel disease. *Ann N Y Acad Sci* 2017; 1401(1): 37–48
  22. He Y, Yuan X, Zuo H, Sun Y, Feng A. Berberine exerts a protective effect on gut-vascular barrier via the modulation of the Wnt/ $\beta$ -catenin signaling pathway during sepsis. *Cell Physiol Biochem* 2018; 49(4): 1342–1351
  23. Wu SJ, Don TM, Lin CW, Mi FL. Delivery of berberine using chitosan/fucoidan-taurine conjugate nanoparticles for treatment of defective intestinal epithelial tight junction barrier. *Mar Drugs* 2014; 12(11): 5677–5697
  24. Shan CY, Yang JH, Kong Y, Wang XY, Zheng MY, Xu YG, Wang Y, Ren HZ, Chang BC, Chen LM. Alteration of the intestinal barrier and GLP2 secretion in berberine-treated type 2 diabetic rats. *J Endocrinol* 2013; 218(3): 255–262
  25. Gu L, Li N, Gong J, Li Q, Zhu W, Li J. Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxemia. *Infect Dis* 2011; 203(11): 1602–1612
  26. Vivoli E, Cappon A, Milani S, Piombanti B, Provenzano A, Novo E, Masi A, Navari N, Narducci R, Mannaioni G, Moneti G, Oliveira CP, Parola M, Marra F. NLRP3 inflammasome as a target of berberine in experimental murine liver injury: interference with P2X7 signalling. *Clin Sci (Lond)* 2016; 130(20): 1793–1806
  27. Guo T, Woo SL, Guo X, Li H, Zheng J, Botchlett R, Liu M, Pei Y, Xu H, Cai Y, Zeng T, Chen L, Li X, Li Q, Xiao X, Huo Y, Wu C. Berberine ameliorates hepatic steatosis and suppresses liver and adipose tissue inflammation in mice with diet-induced obesity. *Sci Rep* 2016; 6(1): 22612–22622
  28. Hwang JM, Wang CJ, Chou FP, Tseng YS, Lin WL, Chu CY. Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative damage in rat liver. *Arch Toxicol* 2002; 76(11): 664–670
  29. Zhao Z, Wei Q, Hua W, Liu Y, Liu X, Zhu Y. Hepatoprotective effects of berberine on acetaminophen-induced hepatotoxicity in mice. *Biomed Pharmacother* 2018; 103: 1319–1326
  30. Rafiei H, Omidian K, Bandy B. Comparison of dietary polyphenols for protection against molecular mechanisms underlying nonalcoholic fatty liver disease in a cell model of steatosis. *Mol Nutr Food Res* 2017; 61(9): 1600781
  31. Qin C, Zhang H, Zhao L, Zeng M, Huang W, Fu G, Zhou W, Wang H, Yan H. Microbiota transplantation reveals beneficial impact of berberine on hepatotoxicity by improving gut homeostasis. *Sci China Life Sci* 2018; 61(12): 1537–1544
  32. Sun Y, Xia M, Yan H, Han Y, Zhang F, Hu Z, Cui A, Ma F, Liu Z, Gong Q, Chen X, Gao J, Bian H, Tan Y, Li Y, Gao X. Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21. *Br J Pharmacol* 2018; 175(2): 374–387
  33. Zhang D, Ke L, Ni Z, Chen Y, Zhang LH, Zhu SH, Li CJ, Shang L, Liang J, Shi YQ. Berberine containing quadruple therapy for initial *Helicobacter pylori* eradication: an open-label randomized phase IV trial. *Medicine (Baltimore)* 2017; 96(32): e7697
  34. Bae FA, Han MJ, Kim NJ, Kim DH. Anti-*Helicobacter pylori* activity of herbal medicines. *Biol Pharm Bull* 1998; 21(9): 990–992
  35. Chung JG, Wu LT, Chang SH, Lo HH, Hsieh SE, Li YC, Hung CF.

- Inhibitory actions of ellagic acid on growth and arylamine N-acetyltransferase activity in strains of *Helicobacter pylori* from peptic ulcer patients. *Microbios* 1998; 93(375): 115–127
36. Li C, Huang P, Wong K, Xu Y, Tan L, Chen H, Lu Q, Luo C, Tam C, Zhu L, Su Z, Xie J. Coptisine-induced inhibition of *Helicobacter pylori*: elucidation of specific mechanisms by probing urease active site and its maturation process. *J Enzyme Inhib Med Chem* 2018; 33(1): 1362–1375
37. Jiang X, Jiang C, Huang C, Chen G, Jiang K, Huang B, Liu F. Berberine combined with triple therapy versus triple therapy for *Helicobacter pylori* eradication: a meta-analysis of randomized controlled trials. *Evid Based Complement Alternat Med* 2018; 2018: 8716910
38. Huang YQ, Huang GR, Wu MH, Tang HY, Huang ZS, Zhou XH, Yu WQ, Su JW, Mo XQ, Chen BP, Zhao LJ, Huang XF, Wei HY, Wei LD. Inhibitory effects of emodin, baicalin, schizandrin and berberine on *hefA* gene: treatment of *Helicobacter pylori*-induced multidrug resistance. *World J Gastroenterol* 2015; 21(14): 4225–4231
39. Zhang X, Yang Y, Gang S, Yang C, Lu M, Zhi J. Berberine-, allicin- or clarithromycin-based triple therapy for the first-line treatment of *Helicobacter pylori* infection: an open-label, randomized trial. *Gastroenterology* 2014; 146(5): S398
40. Lu JS, Liu YQ, Li M, Li BS, Xu Y. Protective effects and its mechanisms of total alkaloids from rhizoma *Coptis chinensis* on *Helicobacter pylori* LPS induced gastric lesion in rats. *China J Chin Mater Med (Zhongguo Zhong Yao Za Zhi)* 2007; 32(13): 1333–1336 (in Chinese)
41. Wu X, Li X, Dang Z, Jia Y. Berberine demonstrates anti-inflammatory properties in *Helicobacter pylori*-infected mice with chronic gastritis by attenuating the Th17 response triggered by the B cell-activating factor. *J Cell Biochem* 2018; 119(7): 5373–5381
42. Kuo CL, Chou CC, Yung BY. Berberine complexes with DNA in the berberine-induced apoptosis in human leukemic HL-60 cells. *Cancer Lett* 1995; 93(2): 193–200
43. Li L, Wang X, Sharvan R, Gao J, Qu S. Berberine could inhibit thyroid carcinoma cells by inducing mitochondrial apoptosis, G0/G1 cell cycle arrest and suppressing migration via PI3K-AKT and MAPK signaling pathways. *Biomed Pharmacother* 2017; 95: 1225–1231
44. Mantena SK, Sharma SD, Katiyar SK. Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. *Mol Cancer Ther* 2006; 5(2): 296–308
45. Lin CC, Yang JL, Lu CC, Chung JG. Berberine induces cell cycle arrest and apoptosis in human HSC-3 oral cancer cells. *FASEB J* 2007; 27(5A):3371–3378
46. Kang JX, Liu J, Wang J, He C, Li FP. The extract of huanglian, a medicinal herb, induces cell growth arrest and apoptosis by upregulation of interferon- $\beta$  and TNF- $\alpha$  in human breast cancer cells. *Carcinogenesis* 2005; 26(11): 1934–1939
47. Zheng F, Tang Q, Wu J, Zhao S, Liang Z, Li L, Wu W, Hann S. p38 $\alpha$  MAPK-mediated induction and interaction of FOXO3a and p53 contribute to the inhibited-growth and induced-apoptosis of human lung adenocarcinoma cells by berberine. *J Exp Clin Cancer Res* 2014; 33(1): 36
48. Liu Q, Xu X, Zhao M, Wei Z, Li X, Zhang X, Liu Z, Gong Y, Shao C. Berberine induces senescence of human glioblastoma cells by downregulating the EGFR-MEK-ERK signaling pathway. *Mol Cancer Ther* 2015; 14(2): 355–363
49. Peng PL, Kuo WH, Tseng HC, Chou FP. Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer: the contribution of autophagic cell death. *Int J Radiat Oncol Biol Phys* 2008; 70(2): 529–542
50. Wu HL, Hsu CY, Liu WH, Yung BY. Berberine-induced apoptosis of human leukemia HL-60 cells is associated with down-regulation of nucleophosmin/B23 and telomerase activity. *Int J Cancer* 1999; 81(6): 923–929
51. Franceschin M, Rossetti L, D'Ambrosio A, Schirripa S, Bianco A, Ortaggi G, Savino M, Schultes C, Neidle S. Natural and synthetic G-quadruplex interactive berberine derivatives. *Bioorg Med Chem Lett* 2006; 16(6): 1707–1711
52. Rocca R, Moraca F, Costa G, Alcaro S, Distinto S, Maccioni E, Ortuso F, Artese A, Parrotta L. Structure-based virtual screening of novel natural alkaloid derivatives as potential binders of h-telo and c-myc DNA G-quadruplex conformations. *Molecules* 2014; 20(1): 206–223
53. Moraca F, Amato J, Ortuso F, Artese A, Pagano B, Novellino E, Alcaro S, Parrinello M, Limongelli V. Ligand binding to telomeric G-quadruplex DNA investigated by funnel-metadynamics simulations. *Proc Natl Acad Sci USA* 2017; 114(11): E2136–E2145
54. Hwang JM, Kuo HC, Tseng TH, Liu JY, Chu CY. Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells. *Arch Toxicol* 2006; 80(2): 62–73
55. Hou D, Xu G, Zhang C, Li B, Qin J, Hao X, Liu Q, Zhang X, Liu J, Wei J, Gong Y, Liu Z, Shao C. Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition. *Cell Death Dis* 2017; 8(10): e3070
56. Shukla S, Rizvi F, Raisuddin S, Kakkar P. FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells. *Free Radic Biol Med* 2014; 76: 185–199
57. Zhang X, Gu L, Li J, Shah N, He J, Yang L, Hu Q, Zhou M. Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. *Cancer Res* 2010; 70(23): 9895–9904
58. Li J, Gu L, Zhang H, Liu T, Tian D, Zhou M, Zhou S. Berberine represses DAXX gene transcription and induces cancer cell apoptosis. *Lab Invest* 2013; 93(3): 354–364
59. Hsu WH, Hsieh YS, Kuo HC, Teng CY, Huang HI, Wang CJ, Yang SF, Liou YS, Kuo WH. Berberine induces apoptosis in SW620 human colonic carcinoma cells through generation of reactive oxygen species and activation of JNK/p38 MAPK and FasL. *Arch Toxicol* 2007; 81(10): 719–728
60. Xiong J, Wang L, Fei XC, Jiang XF, Zheng Z, Zhao Y, Wang CF, Li B, Chen SJ, Janin A, Gale RP, Zhao WL. MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma. *Blood Cancer J* 2017; 7(7): e582
61. Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine *in vitro* and *in vivo*. *Cancer Lett* 2004; 203(2): 127–137
62. Ho YT, Yang JS, Li TC, Lin JJ, Lin JG, Lai KC, Ma CY, Wood WG, Chung JG. Berberine suppresses *in vitro* migration and

- invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF- $\kappa$ B, u-PA and MMP-2 and -9. *Cancer Lett* 2009; 279(2): 155–162
63. Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, Aggarwal BB. Berberine modifies cysteine 179 of I $\kappa$ B $\alpha$  kinase, suppresses nuclear factor- $\kappa$ B-regulated antiapoptotic gene products, and potentiates apoptosis. *Cancer Res* 2008; 68(13): 5370–5379
64. Li D, Zhang Y, Liu K, Zhao Y, Xu B, Xu L, Tan L, Tian Y, Li C, Zhang W, Cao H, Zhan YY, Hu T. Berberine inhibits colitis-associated tumorigenesis via suppressing inflammatory responses and the consequent EGFR signaling-involved tumor cell growth. *Lab Invest* 2017; 97(11): 1343–1353
65. Han X, Tai H, Wang X, Wang Z, Zhou J, Wei X, Ding Y, Gong H, Mo C, Zhang J, Qin J, Ma Y, Huang N, Xiang R, Xiao H. AMPK activation protects cells from oxidative stress-induced senescence via autophagic flux restoration and intracellular NAD(+) elevation. *Aging Cell* 2016; 15(3): 416–427
66. Ruan H, Zhan YY, Hou J, Xu B, Chen B, Tian Y, Wu D, Zhao Y, Zhang Y, Chen X, Mi P, Zhang L, Zhang S, Wang X, Cao H, Zhang W, Wang H, Li H, Su Y, Zhang XK, Hu T. Berberine binds RXR $\alpha$  to suppress  $\beta$ -catenin signaling in colon cancer cells. *Oncogene* 2017; 36(50): 6906–6918
67. Li J, Cao B, Liu X, Fu X, Xiong Z, Chen L, Sartor O, Dong Y, Zhang H. Berberine suppresses androgen receptor signaling in prostate cancer. *Mol Cancer Ther* 2011; 10(8): 1346–1356
68. Ayati SH, Fazeli B, Momtazi-Borojeni AA, Cicero AFG, Pirro M, Sahebkar A. Regulatory effects of berberine on microRNome in cancer and other conditions. *Crit Rev Oncol Hematol* 2017; 116: 147–158
69. Kim S, Oh SJ, Lee J, Han J, Jeon M, Jung T, Lee SK, Bae SY, Kim J, Gil WH, Kim SW, Lee JE, Nam SJ. Berberine suppresses TPA-induced fibronectin expression through the inhibition of VEGF secretion in breast cancer cells. *Cell Physiol Biochem* 2013; 32(5): 1541–1550
70. Qi HW, Xin LY, Xu X, Ji XX, Fan LH. Epithelial-to-mesenchymal transition markers to predict response of berberine in suppressing lung cancer invasion and metastasis. *J Transl Med* 2014; 12(1): 22
71. Yu CS, Kuo HM, Chung JG. The role of cyclooxygenase-2 in berberine induced apoptosis and inhibited cell migration of human gastric adenocarcinoma RF-1 and RF-48 cell lines. *FASEB J* 2006; 20(5):A1131
72. Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS, Lim JS. Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. *Biochem Pharmacol* 2012; 83(3): 385–394
73. Lin JP, Yang JS, Wu CC, Chung JG. Berberine induced down-regulation of matrix metalloproteinases-1, -2, and -7 expressions were associated with levels of reactive oxygen species in human gastric cancer cells (SNU-5) *in vitro*. *FASEB J* 2006; 20(5): A1145
74. Kim S, Lee J, You D, Jeong Y, Jeon M, Yu J, Kim SW, Nam SJ, Lee JE. Berberine suppresses cell motility through downregulation of TGF- $\beta$ 1 in triple negative breast cancer cells *Cell. Physiol Biochem* 2018; 45(2): 795–807
75. Liu SJ, Sun YM, Tian DF, He YC, Zeng L, He Y, Ling CQ, Sun SH. Downregulated NM23-H1 expression is associated with intracranial invasion of nasopharyngeal carcinoma. *Br J Cancer* 2008; 98(2): 363–369
76. Tang F, Wang D, Duan C, Huang D, Wu Y, Chen Y, Wang W, Xie C, Meng J, Wang L, Wu B, Liu S, Tian D, Zhu F, He Z, Deng F, Cao Y. Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine 567. *J Biol Chem* 2009; 284(40): 27456–27466
77. Yang X, Yang B, Cai J, Zhang C, Zhang Q, Xu L, Qin Q, Zhu H, Ma J, Tao G, Cheng H, Sun X. Berberine enhances radiosensitivity of esophageal squamous cancer by targeting HIF-1 $\alpha$  *in vitro* and *in vivo*. *Cancer Biol Ther* 2013; 14(11): 1068–1073
78. Pan Y, Shao D, Zhao Y, Zhang F, Zheng X, Tan Y, He K, Li J, Chen L. Berberine reverses hypoxia-induced chemoresistance in breast cancer through the inhibition of AMPK-HIF-1 $\alpha$ . *Int J Biol Sci* 2017; 13(6): 794–803
79. Chen Q, Qin R, Fang Y, Li H. Berberine sensitizes human ovarian cancer cells to cisplatin through miR-93/PTEN/Akt signaling pathway. *Cell Physiol Biochem* 2015; 36(3): 956–965
80. Mitani N, Murakami K, Yamaura T, Ikeda T, Saiki I. Inhibitory effect of berberine on the mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma. *Cancer Lett* 2001; 165(1): 35–42
81. Fan XX, Leung EL, Xie Y, Liu ZQ, Zheng YF, Yao XJ, Lu LL, Wu JL, He JX, Yuan ZW, Fu J, Wei CL, Huang J, Xiao DK, Luo LX, Jiang ZB, Zhou YL, Kam RK, Liu L. Suppression of lipogenesis via reactive oxygen species-AMPK signaling for treating malignant and proliferative diseases. *Antioxid Redox Signal* 2018; 28(5): 339–357
82. Zhao Y, Cui L, Pan Y, Shao D, Zheng X, Zhang F, Zhang H, He K, Chen L. Berberine inhibits the chemotherapy-induced repopulation by suppressing the arachidonic acid metabolic pathway and phosphorylation of FAK in ovarian cancer. *Cell Prolif* 2017; 50(6): e12393
83. Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. *Am J Physiol Endocrinol Metab* 2008; 294(1): E148–E156
84. Zhou L, Yang Y, Wang X, Liu S, Shang W, Yuan G, Li F, Tang J, Chen M, Chen J. Berberine stimulates glucose transport through a mechanism distinct from insulin. *Metabolism* 2007; 56(3): 405–412
85. Ma X, Egawa T, Kimura H, Karaike K, Masuda S, Iwanaka N, Hayashi T. Berberine-induced activation of 5'-adenosine monophosphate-activated protein kinase and glucose transport in rat skeletal muscles. *Metabolism* 2010; 59(11): 1619–1627
86. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C, Gosby A, Kraegen EW, James DE, Kim JB. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. *Diabetes* 2006; 55(8): 2256–2264
87. Kong WJ, Zhang H, Song DQ, Xue R, Zhao W, Wei J, Wang YM, Shan N, Zhou ZX, Yang P, You XF, Li ZR, Si SY, Zhao LX, Pan HN, Jiang JD. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. *Metabolism* 2009; 58(1): 109–119
88. Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, Wang SK, Zhou ZX, Song DQ, Wang YM, Pan HN, Kong WJ, Jiang JD. Berberine lowers blood glucose in type 2 diabetes mellitus patients

- through increasing insulin receptor expression. *Metabolism* 2010; 59(2): 285–292
89. Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, Kim WS, Kim JB. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. *Am J Physiol Endocrinol Metab* 2009; 296(4): E955–E964
90. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, Taketo MM, Cooney GJ, Kraegen EW, James DE, Hu LH, Li J, Ye JM. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. *Diabetes* 2008; 57(5): 1414–1418
91. Gomes AP, Duarte FV, Nunes P, Hubbard BP, Teodoro JS, Varela AT, Jones JG, Sinclair DA, Palmeira CM, Rolo AP. Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. *Biochim Biophys Acta* 2012; 1822(2): 185–195
92. Wang Y, Shou JW, Li XY, Zhao ZX, Fu J, He CY, Feng R, Ma C, Wen BY, Guo F, Yang XY, Han YX, Wang LL, Tong Q, You XF, Lin Y, Kong WJ, Si SY, Jiang JD. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. *Metabolism* 2017; 70: 72–84
93. Deng Y, Xu J, Zhang X, Yang J, Zhang D, Huang J, Lv P, Shen W, Yang Y. Berberine attenuates autophagy in adipocytes by targeting BECN1. *Autophagy* 2014; 10(10): 1776–1786
94. Chen Y, Li Y, Wang Y, Wen Y, Sun C. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions. *Metabolism* 2009; 58(12): 1694–1702
95. Li A, Liu Q, Li Q, Liu B, Yang Y, Zhang N. Berberine reduces pyruvate-driven hepatic glucose production by limiting mitochondrial import of pyruvate through mitochondrial pyruvate carrier 1. *EBioMedicine* 2018; 34: 243–255
96. Yin J, Hu R, Chen M, Tang J, Li F, Yang Y, Chen J. Effects of berberine on glucose metabolism *in vitro*. *Metabolism* 2002; 51(11): 1439–1443
97. Liu L, Liu J, Gao Y, Yu X, Xu G, Huang Y. Uncoupling protein-2 mediates the protective action of berberine against oxidative stress in rat insulinoma INS-1E cells and in diabetic mouse islets. *Br J Pharmacol* 2014; 171(13): 3246–3254
98. Dong L, Geng FH, Zhang Z, Zhang P, Xing WJ, Dong MQ, Chen KK, Yan WJ, Li J, Fu F, Zhao ZJ, Gao F. GW24-e2332 Berberine alleviates mesenteric artery endothelial dysfunction by improving insulin sensitivity in type 2 diabetic rats. *Heart* 2013; 99(Suppl 3): A100–A101
99. Geng FH, Li GH, Zhang X, Zhang P, Dong MQ, Zhao ZJ, Zhang Y, Dong L, Gao F. Berberine improves mesenteric artery insulin sensitivity through up-regulating insulin receptor-mediated signaling in diabetic rats. *Br J Pharmacol* 2016; 173(10): 1569–1579
100. Ma YG, Zhang YB, Bai YG, Dai ZJ, Liang L, Liu M, Xie MJ, Guan HT. Berberine alleviates the cerebrovascular contractility in streptozotocin-induced diabetic rats through modulation of intracellular  $Ca^{2+}$  handling in smooth muscle cells. *Cardiovasc Diabetol* 2016; 15(1): 63
101. Moghaddam HK, Baluchnejadmojarad T, Roghani M, Khaksari M, Norouzi P, Ahoie M, Mahboobi F. Berberine ameliorate oxidative stress and astrogliosis in the hippocampus of STZ-induced diabetic rats. *Mol Neurobiol* 2014; 49(2): 820–826
102. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. *Nat Med* 2004; 10(12): 1344–1351
103. Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G, Bruckert E, Descamps O, Djuric DM, Ezhov M, Fras Z, von Haehling S, Katsiki N, Langlois M, Latkovskis G, Mancini GBJ, Mikhailidis DP, Mitchenko O, Moriarty PM, Muntner P, Nikolic D, Panagiotakos DB, Paragh G, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Rosano GMC, Rosenson RS, Rysz J, Sahebkar A, Serban MC, Vinereanu D, Vrablik M, Watts GF, Wong ND, Rizzo M. The role of nutraceuticals in statin intolerant patients. *J Am Coll Cardiol* 2018; 72(1): 96–118
104. Singh AB, Li H, Kan CF, Dong B, Nicolls MR, Liu J. The critical role of mRNA destabilizing protein heterogeneous nuclear ribonucleoprotein D in 3' untranslated region-mediated decay of low-density lipoprotein receptor mRNA in liver tissue. *Arterioscler Thromb Vasc Biol* 2014; 34(1): 8–16
105. Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, Oh GT, Park HS, Lee KU, Lane MD, Kim JB. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. *Am J Physiol Endocrinol Metab* 2009; 296(4): E812–E819
106. Zhou L, Wang X, Yang Y, Wu L, Li F, Zhang R, Yuan G, Wang N, Chen M, Ning G. Berberine attenuates cAMP-induced lipolysis via reducing the inhibition of phosphodiesterase in 3T3-L1 adipocytes. *Biochim Biophys Acta* 2011; 1812(4): 527–535
107. Wang Y, Yi X, Ghanam K, Zhang S, Zhao T, Zhu X. Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption. *Metabolism* 2014; 63(9): 1167–1177
108. Sun R, Yang N, Kong B, Cao B, Feng D, Yu X, Ge C, Huang J, Shen J, Wang P, Feng S, Fei F, Guo J, He J, Aa N, Chen Q, Pan Y, Schumacher JD, Yang CS, Guo GL, Aa J, Wang G. Orally administered berberine modulates hepatic lipid metabolism by altering microbial bile acid metabolism and the intestinal FXR signaling pathway. *Mol Pharmacol* 2017; 91(2): 110–122
109. Choi BH, Ahn IS, Kim YH, Park JW, Lee SY, Hyun CK, Do MS. Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. *Exp Mol Med* 2006; 38(6): 599–605
110. Zhang Z, Zhang H, Li B, Meng X, Wang J, Zhang Y, Yao S, Ma Q, Jin L, Yang J, Wang W, Ning G. Berberine activates thermogenesis in white and brown adipose tissue. *Nat Commun* 2014; 5(1): 5493
111. Zhang X, Zhao Y, Xu J, Xue Z, Zhang M, Pang X, Zhang X, Zhao L. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. *Sci Rep* 2015; 5(1): 14405
112. Sun H, Liu Q, Hu H, Jiang Y, Shao W, Wang Q, Jiang Z, Gu A. Berberine ameliorates blockade of autophagic flux in the liver by regulating cholesterol metabolism and inhibiting COX2-prostaglandin synthesis. *Cell Death Dis* 2018; 9(8): 824
113. Marin-Neto JA, Maciel BC, Secches AL, Gallo Júnior L.

- Cardiovascular effects of berberine in patients with severe congestive heart failure. *Clin Cardiol* 1988; 11(4): 253–260
114. Tsui H, Zi M, Wang S, Chowdhury SK, Prehar S, Liang Q, Cartwright EJ, Lei M, Liu W, Wang X. Smad3 couples Pak1 with the antihypertrophic pathway through the E3 ubiquitin ligase, Fbxo32. *Hypertension* 2015; 66(6): 1176–1183
115. Salehi S, Filtz TM. Berberine possesses muscarinic agonist-like properties in cultured rodent cardiomyocytes. *Pharmacol Res* 2011; 63(4): 335–340
116. Huang WM, Wu ZD, Gan YQ. Effects of berberine on ischemic ventricular arrhythmia. *Chin J Cardiovasc Med (Zhonghua Xin Xue Guan Bing Za Zhi)* 1989; 17(5): 300–319 (in Chinese)
117. Sánchez-Chapula J. Increase in action potential duration and inhibition of the delayed rectifier outward current IK by berberine in cat ventricular myocytes. *Br J Pharmacol* 1996; 117(7): 1427–1434
118. Li BX, Yang BF, Zhou J, Xu CQ, Li YR. Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes. *Acta Pharmacol Sin* 2001; 22(2): 125–131
119. Wang LH, Yu CH, Fu Y, Li Q, Sun YQ. Berberine elicits anti-arrhythmic effects via IK1/Kir2.1 in the rat type 2 diabetic myocardial infarction model. *Phytother Res* 2011; 25(1): 33–37
120. Wang LH, Li XL, Li Q, Fu Y, Yu HJ, Sun YQ, Zhang L, Shan HL. Berberine alleviates ischemic arrhythmias via recovering depressed Ito and Ica currents in diabetic rats. *Phytomedicine* 2012; 19(3–4): 206–210
121. Derosa G, D'Angelo A, Bonaventura A, Bianchi L, Romano D, Maffioli P. Effects of berberine on lipid profile in subjects with low cardiovascular risk. *Expert Opin Biol Ther* 2013; 13(4): 475–482
122. Ruscica M, Gomaraschi M, Mombelli G, Macchi C, Bosisio R, Pazzucconi F, Pavanello C, Calabresi L, Arnoldi A, Sirtori CR, Magni P. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus. *J Clin Lipidol* 2014; 8(1): 61–68
123. Fogacci F, Grassi D, Rizzo M, Cicero AFG. Metabolic effect of berberine-silymarin association: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. *Phytother Res* 2019; 33(4): 862–870
124. Wang Y, Huang Y, Lam KS, Li Y, Wong W, Ye H, Lau CW, Vanhoutte PM, Xu A. Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. *Cardiovasc Res* 2009; 82(3): 484–492
125. Cicero AFG, Fogacci F, Colletti A. Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach. *Food Funct* 2017; 8(6): 2076–2088
126. Cicero AF, Baggioni A. Berberine and its role in chronic disease. *Adv Exp Med Biol* 2016; 928: 27–45
127. Caliceti C, Franco P, Spinuzzi S, Roda A, Cicero AF. Berberine: new insights from pharmacological aspects to clinical evidences in the management of metabolic disorders. *Curr Med Chem* 2016; 23(14): 1460–1476
128. Caliceti C, Rizzo P, Cicero AF. Potential benefits of berberine in the management of perimenopausal syndrome. *Oxid Med Cell Longev* 2015; 2015: 723093
129. Yu L, Li Q, Yu B, Yang Y, Jin Z, Duan W, Zhao G, Zhai M, Liu L, Yi D, Chen M, Yu S. Berberine attenuates myocardial ischemia/reperfusion injury by reducing oxidative stress and inflammation response: role of silent information regulator 1. *Oxid Med Cell Longev* 2016; 2016: 1689602
130. Huang ZQ, Ye BZ, Huang WJ. GW24-e1352 Berberine mitigated cardiac hypoxia-reoxygenation injury by suppressed autophagy and reduced cell death via inhibition of the activation of AMPK-mTOR signalling pathway in rat H9c2 cells. *Heart* 2013; 99(Suppl 3): A93
131. Kang DGA, Sohn EJA, Kwon EKA, Han JHA, Oh H, Lee HSAR. Effects of berberine on angiotensin-converting enzyme and NO/cGMP system in vessels. *Vascul Pharmacol* 2002; 39(6): 281–286
132. Kang DG, Sohn EJ, Kwon EK, Han JH, Oh H, Lee HS. Effects of berberine on angiotensin-converting enzyme and NO/cGMP system in vessels. *Vascul Pharmacol* 2002; 39(6): 281–286
133. Caliceti C, Rizzo P, Ferrari R, Fortini F, Aquila G, Leoncini E, Zamboni L, Rizzo B, Calabria D, Simoni P, Mirasoli M, Guardigli M, Hrelia S, Roda A, Cicero AFG. Novel role of the nutraceutical bioactive compound berberine in lectin-like OxLDL receptor 1-mediated endothelial dysfunction in comparison to lovastatin. *Nutr Metab Cardiovasc Dis* 2017; 27(6): 552–563
134. Mazza A, Lenti S, Schiavon L, Zuin M, D'Avino M, Ramazzina E, Casiglia E. Nutraceuticals for serum lipid and blood pressure control in hypertensive and hypercholesterolemic subjects at low cardiovascular risk. *Adv Ther* 2015; 32(7): 680–690
135. Wang J, Guo T, Peng QS, Yue SW, Wang SX. Berberine via suppression of transient receptor potential vanilloid 4 channel improves vascular stiffness in mice. *J Cell Mol Med* 2015; 19(11): 2607–2616
136. Luo J, Gu Y, Liu P, Jiang X, Yu W, Ye P, Chao Y, Yang H, Zhu L, Zhou L, Chen S. Berberine attenuates pulmonary arterial hypertension via protein phosphatase 2A signaling pathway both *in vivo* and *in vitro*. *J Cell Physiol* 2018; 233(12): 9750–9762
137. Liu X, Zhang X, Ye L, Yuan H. Protective mechanisms of berberine against experimental autoimmune myocarditis in a rat model. *Biomed Pharmacother* 2016; 79: 222–230
138. Coelho AR, Martins TR, Couto R, Deus C, Pereira CV, Simões RF, Rizvanov AA, Silva F, Cunha-Oliveira T, Oliveira PJ, Serafim TL. Berberine-induced cardioprotection and Sirt3 modulation in doxorubicin-treated H9c2 cardiomyoblasts. *Biochim Biophys Acta Mol Basis Dis* 2017; 1863(11): 2904–2923
139. Zhang C, Li C, Chen S, Li Z, Jia X, Wang K, Bao J, Liang Y, Wang X, Chen M, Li P, Su H, Wan JB, Lee SMY, Liu K, He C. Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways. *Redox Biol* 2017; 11: 1–11
140. Zhuang W, Li T, Wang C, Shi X, Li Y, Zhang S, Zhao Z, Dong H, Qiao Y. Berberine exerts antioxidant effects via protection of spiral ganglion cells against cytomegalovirus-induced apoptosis. *Free Radic Biol Med* 2018; 121: 127–135
141. Zhu JR, Lu HD, Guo C, Fang WR, Zhao HD, Zhou JS, Wang F, Zhao YL, Li YM, Zhang YD, Yang CQ, Sun JG. Berberine attenuates ischemia-reperfusion injury through inhibiting HMGB1 release and NF- $\kappa$ B nuclear translocation. *Acta Pharmacol Sin* 2018; 39(11): 1706–1715
142. Wang F, Zhao G, Cheng L, Zhou HY, Fu LY, Yao WX. Effects of berberine on potassium currents in acutely isolated CA1 pyramidal neurons of rat hippocampus. *Brain Res* 2004; 999(1): 91–97

143. Sun SWang K, Lei H, Li L, Tu M, Zeng S, Zhou H, Jiang H. Inhibition of organic cation transporter 2 and 3 may be involved in the mechanism of the antidepressant-like action of berberine. *Prog Neuropsychopharmacol Biol Psychiatry* 2014; 49: 1–6
144. Fan J, Li B, Ge T, Zhang Z, Lv J, Zhao J, Wang P, Liu W, Wang X, Mlyniec K, Cui R. Berberine produces antidepressant-like effects in ovariectomized mice. *Sci Rep* 2017; 7(1): 1310
145. Liu YM, Niu L, Wang LL, Bai L, Fang XY, Li YC, Yi LT. Berberine attenuates depressive-like behaviors by suppressing neuro-inflammation in stressed mice. *Brain Res Bull* 2017; 134: 220–227
146. Wang B, Xu X, He X, Wang Z, Yang M. Berberine improved aldosterone-induced podocyte injury via inhibiting oxidative stress and endoplasmic reticulum stress pathways both *in vivo* and *in vitro*. *Cell Physiol Biochem* 2016; 39(1): 217–228
147. Kim BH, Kim M, Yin CH, Jee JG, Sandoval C, Lee H, Bach EA, Hahm DH, Baeg GH. Inhibition of the signalling kinase JAK3 alleviates inflammation in monoarthritic rats. *Br J Pharmacol* 2011; 164(1): 106–118
148. Lee HW, Suh JH, Kim HN, Kim AY, Park SY, Shin CS, Choi JY, Kim JB. Berberine promotes osteoblast differentiation by Runx2 activation with p38 MAPK. *J Bone Miner Res* 2008; 23(8): 1227–1237
149. Robinson CL, Chong ACN, Ashbrook AW, Jeng G, Jin J, Chen H, Tang EI, Martin LA, Kim RS, Kenyon RM, Do E, Luna JM, Saeed M, Zeltser L, Ralph H, Dudley VL, Goldstein M, Rice CM, Cheng CY, Seandel M, Chen S. Male germ cells support long-term propagation of Zika virus. *Nat Commun* 2018; 9(1): 2090